Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2019

01-02-2019 | Original Article

Hematopoietic stem cell transplantation for subcutaneous panniculitis-like T-cell lymphoma: single center experience in an Asian population

Authors: Ting-An Lin, Ching-Fen Yang, Yao-Chung Liu, Jin-Hwang Liu, Tzeon-jye Chiou, Liang-Tsai Hsiao, Hsiu-Ju Yen, Chia-Jen Liu, Hao-Yuan Wang, Po-Shen Ko, Sheng-Hsuan Chien, Jyh-Pyng Gau

Published in: International Journal of Hematology | Issue 2/2019

Login to get access

Abstract

Subcutaneous panniculitis-like T-cell lymphoma (SPTL) is a rare form of cytotoxic T-cell lymphoma. It is believed that SPTL in patients without hemophagocytic syndrome (HPS) follows an indolent course; in contrast, SPTL in patients with HPS has been associated with unfavorable survival. To provide more clinical data on SPTL in Asian populations and to identify optimal therapeutic strategies for SPTL, we assessed the clinicopathological features and long-term follow-up data of 10 Taiwanese SPTL patients diagnosed at a single center. Our study demonstrates a group of patients with high incidence of HPS (50%), rather aggressive courses, and early progression. A total of eight patients underwent hematopoietic stem cell transplant (HSCT), including one autologous HSCT and seven allogeneic HSCT. Seven of eight patients receiving HSCT achieved durable remission and maintained in remission for over 30 months (range 30–132 months). There was no difference in 3-year survival of patients with HPS (80%) compared with patients without HPS (80%). Of long-term survivors in the HPS group, three of four received HSCT (autologous HSCT, n = 1; allogeneic HSCT, n = 2). Our study indicated that HSCT is a curative option for eligible SPTL patients with HPS.
Literature
1.
Gonzalez CL, Medeiros LJ, Braziel RM, Jaffe ES. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol. 1991;15(1):17–27.CrossRefPubMed
2.
Jaffe ES. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
3.
Salhany KE, Macon WR, Choi JK, Elenitsas R, Lessin SR, Felgar RE, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol. 1998;22(7):881–93.CrossRefPubMed
4.
Hoque SR, Child FJ, Whittaker SJ, Ferreira S, Orchard G, Jenner K, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. 2003;148(3):516–25.CrossRefPubMed
5.
Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer. 2004;101(6):1404–13.CrossRefPubMed
6.
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.CrossRefPubMed
7.
Swerlow SH, World Health O. WHO classification of tumours of haematopoietic and lymphoid tissues: WHO; 2008.
8.
Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111(2):838–45.CrossRefPubMed
9.
Lee DW, Yang JH, Lee SM, Won CH, Chang S, Lee MW, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinical and pathologic study of 14 korean patients. Ann Dermatol. 2011;23(3):329–37.CrossRefPubMedPubMedCentral
10.
Oschlies I, Simonitsch-Klupp I, Maldyk J, Konovalov D, Abramov D, Myakova N, et al. Subcutaneous panniculitis-like T-cell lymphoma in children: a detailed clinicopathological description of 11 multifocal cases with a high frequency of haemophagocytic syndrome. Br J Dermatol. 2015;172(3):793–7.CrossRefPubMed
11.
Jang MS, Baek JW, Kang DY, Kang JS, Suh KS, Kim ST. Subcutaneous panniculitis-like T-cell lymphoma: successful treatment with systemic steroid alone. J Dermatol. 2012;39(1):96–9.CrossRefPubMed
12.
Briki H, Bouaziz JD, Molinier-Frenkel V, Delfau-Larue MH, Ortonne N, Bagot M. Subcutaneous panniculitis-like T-cell lymphoma alphabeta: complete sustained remission with corticosteroids and methotrexate. Br J Dermatol. 2010;163(5):1136–8.CrossRefPubMed
13.
Tsukamoto Y, Katsunobu Y, Omura Y, Maeda I, Hirai M, Teshima H, et al. Subcutaneous panniculitis-like T-cell lymphoma: successful initial treatment with prednisolone and cyclosporin A. Intern Med. 2006;45(1):21–4.CrossRefPubMed
14.
Lee WS, Hwang JH, Kim MJ, Go SI, Lee A, Song HN, et al. Cyclosporine A as a primary treatment for panniculitis-like T cell lymphoma: a case with a long-term remission. Cancer Res Treat. 2014;46(3):312–6.CrossRefPubMedPubMedCentral
15.
Michonneau D, Petrella T, Ortonne N, Ingen-Housz-Oro S, Franck N, Barete S, et al. Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy. Acta Derm Venereol. 2017;97(3):358–64.CrossRefPubMed
16.
Ghobrial IM, Weenig RH, Pittlekow MR, Qu G, Kurtin PJ, Ristow K, et al. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2005;46(5):703–8.CrossRefPubMed
17.
Ohtsuka M, Miura T, Yamamoto T. Clinical characteristics, differential diagnosis, and treatment outcome of subcutaneous panniculitis-like T-cell lymphoma: a literature review of published Japanese cases. Eur J Dermatol. 2017;27(1):34–41.PubMed
18.
Koh MJ, Sadarangani SP, Chan YC, Chan MY, Tan AM, Tan SH, et al. Aggressive subcutaneous panniculitis-like T-cell lymphoma with hemophagocytosis in two children (subcutaneous panniculitis-like T-cell lymphoma). J Am Acad Dermatol. 2009;61(5):875–81.CrossRefPubMed
19.
Weenig RH, Ng CS, Perniciaro C. Subcutaneous panniculitis-like T-cell lymphoma: an elusive case presenting as lipomembranous panniculitis and a review of 72 cases in the literature. Am J Dermatopathol. 2001;23(3):206–15.CrossRefPubMed
20.
Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.CrossRefPubMed
21.
Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479–84.CrossRefPubMed
22.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.CrossRef
23.
Huppmann AR, Xi L, Raffeld M, Pittaluga S, Jaffe ES. Subcutaneous panniculitis-like T-cell lymphoma in the pediatric age group: a lymphoma of low malignant potential. Pediatr Blood Cancer. 2013;60(7):1165–70.CrossRefPubMedPubMedCentral
24.
Kong YY, Dai B, Kong JC, Zhou XY, Lu HF, Shen L, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic, and molecular study of 22 Asian cases according to WHO-EORTC classification. Am J Surg Pathol. 2008;32(10):1495–502.CrossRefPubMed
25.
Sakurai E, Satoh T, Akiko YA, Maesawa C, Tsunoda K, Endo M, et al. Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) with hemophagocytosis (HPS): successful treatment using high-dose chemotherapy (BFM-NHL & ALL-90) and autologous peripheral blood stem cell transplantation. J Clin Exp Hematop. 2013;53(2):135–40.CrossRefPubMed
26.
Medhi K, Kumar R, Rishi A, Kumar L, Bakhshi S. Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytosis: complete remission with BFM-90 protocol. J Pediatr Hematol Oncol. 2008;30(7):558–61.CrossRefPubMed
27.
Gupta V, Arava S, Bakhshi S, Vashisht KR, Reddy R, Gupta S. Subcutaneous panniculitis-Like T-Cell lymphoma with hemophagocytic syndrome in a child. Pediatr Dermatol. 2016;33(2):e72-6.CrossRefPubMed
28.
Mukai HY, Okoshi Y, Shimizu S, Katsura Y, Takei N, Hasegawa Y, et al. Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation. Eur J Haematol. 2003;70(6):413–6.CrossRefPubMed
29.
Dholaria B, Patel RJ, Sluzevich JC, Ailawadhi S, Roy V. Relapsed subcutaneous panniculitis-like T cell lymphoma: role of haploidentical hematopoietic stem cell transplant. Ann Hematol. 2017;96(12):2125–6.CrossRefPubMed
30.
Brown NA, Ross CW, Gudjonsson JE, Wale D, Pawarode A, Maillard I, et al. Subcutaneous panniculitis-like T-cell lymphoma with bone marrow involvement. Am J Clin Pathol. 2015;143(2):265–73.CrossRefPubMed
31.
Gao J, Gauerke SJ, Martinez-Escala ME, Guitart J, Nelson BP, Chadburn A, et al. Bone marrow involvement by subcutaneous panniculitis-like T-cell lymphoma: a report of three cases. Mod Pathol. 2014;27(6):800–7.CrossRefPubMed
32.
Yuan L, Sun L, Bo J, Zhou Y, Li HH, Yu L, et al. Durable remission in a patient with refractory subcutaneous panniculitis-like T-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation through withdrawal of cyclosporine. Ann Transplant. 2011;16(3):135–8.CrossRefPubMed
33.
Ichii M, Hatanaka K, Imakita M, Ueda Y, Kishino B, Tamaki T. Successful treatment of refractory subcutaneous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA-mismatched sibling donor. Leuk Lymphoma. 2006;47(10):2250–2.CrossRefPubMed
34.
Yokota K, Akiyama Y, Adachi D, Shindo Y, Yoshida Y, Miyoshi F, et al. Subcutaneous panniculitis-like T-cell lymphoma accompanied by Sjogren’s syndrome. Scand J Rheumatol. 2009;38(6):494–5.CrossRefPubMed
35.
Go SI, Lee WS, Kang MH, Kim IS, Kim DC, Lee JH. Cyclosporine A treatment for relapsed subcutaneous panniculitis-like T-cell lymphoma: a case with long-term follow-up. Korean J Hematol. 2012;47(2):146–9.CrossRefPubMedPubMedCentral
36.
Nagai K, Nakano N, Iwai T, Iwai A, Tauchi H, Ohshima K, et al. Pediatric subcutaneous panniculitis-like T-cell lymphoma with favorable result by immunosuppressive therapy: a report of two cases. Pediatr Hematol Oncol. 2014;31(6):528–33.CrossRefPubMed
37.
Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Group EGW. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi149–54.CrossRefPubMed
38.
Wasik F, Kolodziej T, Jelen M, Pejcz J. Subcutaneous T-cell lymphoma: report of two cases. J Eur Acad Dermatol Venereol. 1998;10(1):62–6.CrossRefPubMed
39.
Rudolph N, Klemke CD, Ziemer M, Simon JC, Treudler R. Hemophagocytic lymphohistiocytosis associated with subcutaneous panniculitis-like T-cell lymphoma. J Dtsch Dermatol Ges. 2016;14(11):1140–2.CrossRefPubMed
40.
Bader-Meunier B, Fraitag S, Janssen C, Brochard K, Lamant L, Wouters C, et al. Clonal cytophagic histiocytic panniculitis in children may be cured by cyclosporine A. Pediatrics. 2013;132(2):e545-9.CrossRefPubMed
41.
Chen CC, Teng CL, Yeh SP. Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review. Ann Hematol. 2016;95(5):837–40.CrossRefPubMed
42.
Al Zolibani AA, Al Robaee AA, Qureshi MG, Al Nosian H. Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome successfully treated with cyclosporin A. Skinmed. 2006;5(4):195–7.CrossRefPubMed
43.
44.
Rojnuckarin P, Nakorn TN, Assanasen T, Wannakrairot P, Intragumtornchai T. Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2007;48(3):560–3.CrossRefPubMed
45.
Mizutani S, Kuroda J, Shimura Y, Kobayashi T, Tsutsumi Y, Yamashita M, et al. Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome. Acta Haematol. 2011;126(1):8–12.CrossRefPubMed
46.
Jung HR, Yun SY, Choi JH, Bae SH, Ryoo HM, Kum YS. Cyclosporine in relapsed subcutaneous panniculitis-like T-cell lymphoma after autologous hematopoietic stem cell transplantation. Cancer Res Treat. 2011;43(4):255–9.CrossRefPubMedPubMedCentral
47.
48.
Miura T, Kawakami Y, Sato M, Ohtsuka M, Yamamoto T. Hemophagocytic syndrome occurred in a patient with subcutaneous panniculitis-like T-cell lymphoma without overt skin lesion: successful treatment with steroid pulse therapy. J Dermatol. 2011;38(11):1113–5.CrossRefPubMed
Metadata
Title
Hematopoietic stem cell transplantation for subcutaneous panniculitis-like T-cell lymphoma: single center experience in an Asian population
Authors
Ting-An Lin
Ching-Fen Yang
Yao-Chung Liu
Jin-Hwang Liu
Tzeon-jye Chiou
Liang-Tsai Hsiao
Hsiu-Ju Yen
Chia-Jen Liu
Hao-Yuan Wang
Po-Shen Ko
Sheng-Hsuan Chien
Jyh-Pyng Gau
Publication date
01-02-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-02568-9

Other articles of this Issue 2/2019

International Journal of Hematology 2/2019 Go to the issue

Images in Hematology

Villous lymphocytes in splenic large B-cell lymphoma with diffuse red pulp infiltration

Original Article

Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation

Images in Hematology

Lead poisoning as final diagnosis in a study of normocytic anemia

Original Article

Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan

Original Article

Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma

Original Article

Late-stage myeloma invades kidney without significant effect on renal function: findings from 53 autopsies in a single institute
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits